PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN
    4.
    发明申请
    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN 审中-公开
    生产RIFAXIMIN多形态的方法

    公开(公告)号:US20120214989A1

    公开(公告)日:2012-08-23

    申请号:US13463714

    申请日:2012-05-03

    IPC分类号: C07D498/22

    CPC分类号: C07D498/22

    摘要: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译: 结晶多形态的利福昔明(INN)抗生素名为利福昔明α和利福昔明,并且结晶形式名为利福昔明γ,可用于生产含有利福昔明用于口服和局部使用的药物制剂,并通过结晶进行 将生的利福昔明热溶解在乙醇中,并通过在确定的温度下加入水并在一定的时间内引起产物的结晶,然后在受控条件下进行干燥,直到达到沉淀的含水量 最终产品是本发明的目的。

    Polymorphic forms α, β and γ of rifaximin
    5.
    发明授权
    Polymorphic forms α, β and γ of rifaximin 有权
    多形态α,&bgr; 和利福昔明的γ

    公开(公告)号:US08158781B2

    公开(公告)日:2012-04-17

    申请号:US13041332

    申请日:2011-03-04

    IPC分类号: C07D498/22

    摘要: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译: 结晶多形态的利福昔明(INN)抗生素名为利福昔明α和利福昔明,并且结晶形式名为利福昔明γ,可用于生产含有利福昔明用于口服和局部使用的药物制剂,并通过结晶进行 将生的利福昔明热溶解在乙醇中,并通过在确定的温度下加入水并在一定的时间内引起产物的结晶,然后在受控条件下进行干燥,直到达到沉淀的含水量 最终产品是本发明的目的。

    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN
    8.
    发明申请
    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN 有权
    生产RIFAXIMIN多形态的方法

    公开(公告)号:US20110160449A1

    公开(公告)日:2011-06-30

    申请号:US13041346

    申请日:2011-03-04

    IPC分类号: C07D491/22

    CPC分类号: C07D498/22

    摘要: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译: 结晶多形态的利福昔明(INN)抗生素名为利福昔明α和利福昔明,并且结晶形式名为利福昔明γ,可用于生产含有利福昔明用于口服和局部使用的药物制剂,并通过结晶进行 将生的利福昔明热溶解在乙醇中,并通过在确定的温度下加入水并在一定的时间内引起产物的结晶,然后在受控条件下进行干燥,直到达到沉淀的含水量 最终产品是本发明的目的。

    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN
    9.
    发明申请
    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN 有权
    多聚体形式的阿尔法,BETA和游戏的RIFAXIMIN

    公开(公告)号:US20110160448A1

    公开(公告)日:2011-06-30

    申请号:US13041332

    申请日:2011-03-04

    IPC分类号: C07D498/22

    摘要: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译: 结晶多形态的利福昔明(INN)抗生素名为利福昔明α和利福昔明,并且结晶形式名为利福昔明γ,可用于生产含有利福昔明用于口服和局部使用的药物制剂,并通过结晶进行 将生的利福昔明热溶解在乙醇中,并通过在确定的温度下加入水并在一定的时间内引起产物的结晶,然后在受控条件下进行干燥,直到达到沉淀的含水量 最终产品是本发明的目的。